Logo

MiNK Therapeutics, Inc.

INKT

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is… read more

Healthcare

Biotechnology

1 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$14.15

Price

+1.07%

$0.15

Market Cap

$63.976m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$3.769b

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$2.775b

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$2.87

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

-$25.189m

$2.484m

Assets

$27.674m

Liabilities

$5.506m

Debt
Debt to Assets

221.6%

-0.5x

Debt to EBITDA
Free Cash Flow

-$1.347b

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases